New inhaled therapy aims to slow lung scarring in IPF
NCT ID NCT07194382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low or high dose of AP02 or a placebo twice daily for 12 weeks using a nebulizer. The goal is to see if AP02 improves lung function and is safe and well-tolerated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIC Mauricie
ACTIVE_NOT_RECRUITINGTrois-Rivières, Quebec, G8T 7A1, Canada
-
Dynamic Drug Advancement
RECRUITINGAjax, Ontario, L1S2J5, Canada
-
Nepean Lung and Sleep
RECRUITINGKingswood, New South Wales, 2747, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease
- New hope for lung scarring: AZD8965 enters Mid-Stage trial